^
Association details:
| Biomarker: | MSH2 deletion + MSH6 deletion |
|---|---|
| Cancer: | Pituitary Gland Carcinoma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
Excerpt:
Loss of MSH2 and MSH 6 was observed in a single patient who had a rapid development of resistance to TMZ.
DOI:
10.1210/jc.2014-4350
